Sidney Pitt

Bristol-Myers Squibb (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index2.6kcitations28works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(17), Synthesis and biological activity(8), Computational Drug Discovery Methods(7), Cytokine Signaling Pathways and Interactions(5), Synthesis and Characterization of Heterocyclic Compounds(5)

Publications28 total

Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis
ACS Medicinal Chemistry Letters·2019· 14 citedOpen Access
CCDC 1896615: Experimental Crystal Structure Determination
The Cambridge Structural Database·2019Open Access
Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders
Journal of Medicinal Chemistry·2017· 22 citedOpen Access
Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors
Bioorganic & Medicinal Chemistry Letters·2017· 13 citedOpen Access
Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors
Bioorganic & Medicinal Chemistry Letters·2014· 30 citedOpen Access
The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode
Bioorganic & Medicinal Chemistry Letters·2013· 15 citedOpen Access
Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors
Bioorganic & Medicinal Chemistry Letters·2011· 13 citedOpen Access
5-Amino-pyrazoles as potent and selective p38α inhibitors
Bioorganic & Medicinal Chemistry Letters·2010· 21 citedOpen Access
Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-<i>N</i>-propylpyrrolo[1,2-<i>f</i>][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases
Journal of Medicinal Chemistry·2010· 57 citedOpen Access
Utilization of a nitrogen–sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors
Bioorganic & Medicinal Chemistry Letters·2010· 31 citedOpen Access
Dasatinib Once-Daily Dose Regimen Provides Robust Anti-Leukemic Activity While Avoiding Suppression of T Cell Activation.
Blood·2009
Dasatinib potential for anti-inflammatory efficacy while avoiding suppression of T cell activation in preclinical models (33.8)
The Journal of Immunology·2009· 2 cited
Pyrazolo-pyrimidines: A novel heterocyclic scaffold for potent and selective p38α inhibitors
Bioorganic & Medicinal Chemistry Letters·2008· 42 citedOpen Access
Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38α MAP kinase inhibitors
Bioorganic & Medicinal Chemistry Letters·2008· 31 citedOpen Access
The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)—A potent and efficacious p38α MAP kinase inhibitor
Bioorganic & Medicinal Chemistry Letters·2008· 26 citedOpen Access
Benzothiazole based inhibitors of p38α MAP kinase
Bioorganic & Medicinal Chemistry Letters·2008· 50 citedOpen Access
Design, Synthesis, and Anti-inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-<i>f</i>][1,2,4]triazine p38α Mitogen-Activated Protein Kinase Inhibitors
Journal of Medicinal Chemistry·2007· 81 citedOpen Access
Synthesis and SAR of p38α MAP kinase inhibitors based on heterobicyclic scaffolds
Bioorganic & Medicinal Chemistry Letters·2007· 23 citedOpen Access
2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure−Activity Relationship Studies toward the Discovery of <i>N</i> -(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent <i>pan</i> -Src Kinase Inhibitor
Journal of Medicinal Chemistry·2006· 393 citedOpen Access
5-Cyanopyrimidine Derivatives as a Novel Class of Potent, Selective, and Orally Active Inhibitors of p38α MAP Kinase
Journal of Medicinal Chemistry·2005· 70 cited
page 1 of 2Next →

Frequent Co-authors

Gary L. Schieven(27), Joel C. Barrish(24), Arthur M. Doweyko(20), John S. Sack(17), Kim W. McIntyre(16), Ding Ren Shen(15), Kathleen M. Gillooly(14), Rosemary Zhang(13), John H. Dodd(13), Katerina Leftheris(13), Stephen T. Wrobleski(12), Murray McKinnon(11), John Wityak(10), David J. Shuster(9), John Hynes(9), Susan E. Kiefer(9), Kevin Kish(9), Jagabandhu Das(8), James C. Lin(8), Shuqun Lin(8)